Clinical proteomics of the neglected human malarial parasite plasmodium vivax

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Acharya, Pragyan ^a   Pallavi, Rani ^a   Chandran, Syama ^a   Dandavate, Vrushali ^a   Sayeed, Syed Khund ^a   Rochani, Ankit ^a   Acharya, Jyoti ^b   Middha, Sheetal ^b   Kochar, Sanjay ^b   Kochar, Dhanpat ^b   Ghosh, Susanta Kumar ^c   Tatu, Utpal ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b S P MEDICAL COLLEGE   (India)

^c NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATP DEPENDENT RNA HELICASE; CYCLOPHILIN; DIHYDROLIPOYLLYSINE RESIDUE SUCCINYLTRANSFERASE COMPONENT OF 2 OXOGLUTARATE DEHYDROGENASE COMPLEX; DUFFY RECEPTOR PRECURSOR PROTEIN; ELONGATION FACTOR 1ALPHA; ELONGATION FACTOR 1BETA; PROTEOME; PROTOZOAL PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; VACUOLAR ATP SYNTHASE SUBUNIT E; MALARIA VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FUNCTIONAL PROTEOMICS; NONHUMAN; PARASITE ISOLATION; PLASMODIUM VIVAX; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LIFE CYCLE STAGE; MALARIA; METABOLISM; PARASITOLOGY; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SEQUENCE HOMOLOGY;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

ANIMALS; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM VIVAX; PROTEIN INTERACTION MAPS; PROTEOMICS; PROTOZOAN PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTOME;

EID: 80054793079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026623     Document Type: Article

References (41)

1. Mendis K, Sina BJ, Marchesini P, Carter R, (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106.
2. Galinski MR, Barnwell JW, (2008) Plasmodium vivax: who cares? Malar J 7 (Suppl 1): S9.
3. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, et al. (2008) Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455: 757-763.
4. Trager W, Jensen JB, (1976) Human malaria parasites in continuous culture. Science 193: 673-675.
5. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, et al. (2008) The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci U S A 105: 16290-16295.
6. Westenberger SJ, McClean CM, Chattopadhyay R, Dharia NV, Carlton JM, et al. (2010) A systems-based analysis of Plasmodium vivax lifecycle transcription from human to mosquito. PLoS Negl Trop Dis 4: e653.
7. Roobsong W, Roytrakul S, Sattabongkot J, Li J, Udomsangpetch, et al. (2011) Determination of the Plasmodium vivax schizont stage proteome. J Proteomics. Apr 13.
8. Huh Ae-J, Kwak YE, Kim ES, Lee KS, Yeom Joon-S, et al. (2011) Parasitemia Characteristics of Plasmodium vivax Malaria Patients in the Republic of Korea. J Korean Med Sci 26: 42-46.
9. Acharya P, Pallavi R, Chandran S, Chakravarti H, Middha S, et al. (2009) A glimpse into the clinical proteome of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Proteomics Clin appl 3: 1314-1325.
10. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, et al. (2002) A proteomic view of the Plasmodium falciparum life cycle. Nature 419: 520-526.
11. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, et al. (2004) Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res 14: 2308-2318.
12. Fried M, Hixson KK, Anderson L, Ogata Y, Mutabingwa TK, et al. (2007) The distinct proteome of placental malaria parasites. Mol Biochem Parasitol 155: 57-65.
13. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, et al. (1996) Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 379: 466-469.
14. Ersmark K, Nervall M, Gutierrez-de-Teran H, Hamelink E, Janka LK, et al. (2006) Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg Med Chem 14: 2197-2208.
15. McGowan S, Porter CJ, Lowther J, Stack CM, Golding SJ, et al. (2009) Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci U S A 106: 2537-2542.
16. Trenholme KR, Brown CL, Skinner-Adams TS, Stack C, Lowther J, et al. (2010) Aminopeptidases of malaria parasites: new targets for chemotherapy. Infect Disord Drug Targets 10: 217-225.
17. Becker JV, Mtwisha L, Crampton BG, Stoychev S, van Brummelen AC, et al. (2010) Plasmodium falciparum spermidine synthase inhibition results in unique perturbation-specific effects observed on transcript, protein and metabolite levels. BMC Genomics 11: 235.
18. Itin C, Burki Y, Certa U, Dobeli H, (1993) Selective inhibition of Plasmodium falciparum aldolase by a tubulin derived peptide and identification of the binding site. Mol Biochem Parasitol 58: 135-143.
19. Kim H, Certa U, Dobeli H, Jakob P, Hol WG, (1998) Crystal structure of fructose-1,6-bisphosphate aldolase from the human malaria parasite Plasmodium falciparum. Biochemistry 37: 4388-4396.
20. Wanidworanun C, Nagel RL, Shear HL, (1999) Antisense oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum. Mol Biochem Parasitol 102: 91-101.
21. Wrenger C, Eschbach ML, Muller IB, Warnecke D, Walter RD, (2005) Analysis of the vitamin B6 biosynthesis pathway in the human malaria parasite Plasmodium falciparum. J Biol Chem 280: 5242-5248.
22. Velanker SS, Ray SS, Gokhale RS, Suma S, Balaram H, et al. (1997) Triosephosphate isomerase from Plasmodium falciparum: the crystal structure provides insights into antimalarial drug design. Structure 5: 751-761.
23. Joubert F, Neitz AW, Louw AI, (2001) Structure-based inhibitor screening: a family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase. Proteins 45: 136-143.
24. Granchi C, Bertini S, Macchia M, Minutolo F, (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17: 672-697.
25. Banumathy G, Singh V, Pavithra SR, Tatu U, (2003) Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 278: 18336-18345.
26. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, et al. (2010) Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285: 37964-37975.
27. Pesce ER, Cockburn IL, Chiang AN, Valderramos JC, Balachandran R, et al. (2009) Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg Med Chem 17: 1527-1533.
28. Pesce ER, Cockburn IL, Goble JL, Stephens LL, Blatch GL, (2010) Malaria heat shock proteins: drug targets that chaperone other drug targets. Infect Disord Drug Targets 10: 147-157.
29. Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, et al. (1997) Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun 65: 2772-2777.
30. Fernandez-Becerra C, Yamamoto MM, Vencio RZ, Lacerda M, Rosanas-Urgell A, et al. (2009) Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol 25: 44-51.
31. Jalah R, Sarin R, Sud N, Alam MT, Parikh N, et al. (2005) Identification, expression, localization and serological characterization of a tryptophan-rich antigen from the human malaria parasite Plasmodium vivax. Mol Biochem Parasitol 142: 158-169.
32. Daily JP, Scanfeld D, Pochet N, Le Roch K, Plouffe D, et al. (2007) Distinct physiological states of Plasmodium falciparum in malaria-infected patients. Nature 450: 1091-1095.
33. LeRoux M, Lakshmanan V, Daily JP, (2009) Plasmodium falciparum biology: analysis of in vitro versus in vivo growth conditions. Trends Parasitol 25: 474-481.
34. LaCount DJ, Vignali M, Chettier R, Phansalkar A, Bell R, et al. (2005) A protein interaction network of the malaria parasite Plasmodium falciparum. Nature 438: 103-107.
35. Date SV, Stoeckert CJ Jr, (2006) Computational modeling of the Plasmodium falciparum interactome reveals protein function on a genome-wide scale. Genome Res 16: 542-549.
36. Price RN, Douglas NM, Anstey NM, (2009) New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22: 430-435.
37. Baird JK, Schwartz E, Hoffman SL, (2007) Prevention and treatment of vivax malaria. Curr Infect Dis Rep 9: 39-46.
38. Collins WE, Jeffery GM, (1996) Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 55: 243-249.
39. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, et al. (2004) Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 48: 2214-2222.
40. Dharia NV, Bright AT, Westenberger SJ, Barnes SW, Batalov S, et al. (2010) Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci U S A 107: 20045-20050.
41. Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, et al. (2007) The human reticulocyte transcriptome. Physiol Genomics 30: 172-178.